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Abstract
While tumor resection and liver transplantation (LT) represent potentially curative therapeu-
tic options for patients with early-stage hepatocellular carcinoma (HCC), the identification of
the ideal surgical candidates has remained challenging. Just recently, miRNA-193a-5p was
described as a tumor suppressor in murine and human HCC but only little is known about
circulating miRNA-193a-5p in HCC patients. Here, we evaluated serum levels of miR-193a-
5p by qPCR in 41 HCC patients undergoing tumor resection (n = 33) or LT (n = 8) and 20
controls. Circulating relative miR-193a-5p levels were significantly elevated in HCC patients
compared to healthy controls. While relative miR-193a-5p levels were comparable between
patients of different underlying disease etiology and tumor size, high relative miR-193a-5p
levels were predictive for the patients’ postoperative outcome, which was confirmed in uni-
and multivariate Cox-regression analysis. As such, HCC patients with a preoperative rela-
tive miR-193a-5p level above the ideal cut-off value (3.57) had a median overall survival
(OS) of only 451 days compared to 1158 days in patients with a relative miR-193a-5p level
below this cut-off value. Our data support a novel function of miR-193a-5p as a biomarker in
early-stage HCC patients that might help to identify the best surgical candidates in terms of
postoperative outcome.
Introduction
Hepatocellular carcinoma (HCC) represents the most common primary liver cancer and is
associated with rising incidence rates [1]. While the majority of patients initially present with
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an advanced non-resectable tumor stage (BCLC B or C) and are assigned to systemic chemo-
therapy or local ablative approaches (e.g. transarterial chemoembolization (TACE)), curatively
indented surgical tumor resection as well as liver transplantation (LT) represent the standard
of care for early stage HCC patients (BCLC 0 or A) [2]. However, despite receiving a complete
tumor resection around 70% of patients develop disease recurrence within five years [3].
Moreover, surgical resection is related to postoperative complications including liver failure,
infections and delirium, which might be associated with a prolonged hospital stay as well as an
unfavourable outcome after surgery [4]. Despite several prognostic algorithms and preopera-
tive assessment strategies (including laboratory parameters, imaging techniques as well as the
patients’ clinical performance status) have been proposed so far [5], identification of patients
that particularly benefit from liver resection or LT in terms of overall survival (OS) still repre-
sent a major clinical challenge.
Micro RNAs (miRNA) are a group of small RNA that regulate gene expression on a post-
transcriptional and posttranslational level [6]. During the past decade, miRNAs were estab-
lished as both tumor suppressors and oncogenes in different malignancies including HCC [7,
8]. We recently identified down-regulation of miR-193a-5p as a common feature of murine
and human HCC regardless of the disease etiology [9]. By reducing levels of nucleolar and
spindle-associated protein 1 (NUSAP-1), miR-193a-5p prevented the development of HCC
and lower expression of miR-193a-5p was directly associated with shorter survival times of
patients. Besides their function as intracellular regulators of gene expression, miRNAs are
increasingly used as blood-based biomarkers for manifold biological processes. In HCC, vari-
ous circulating miRNAs were proposed as both diagnostic and prognostic markers [10, 11].
However, the use of these miRNAs in clinical routine was hampered by a tremendous lack in
data standardization, reproducibility as well as a lack of biological rationale explaining the
observed regulation of certain miRNAs.
Based on the compelling functional data on miR-193a-5p in human and murine HCC [9],
we performed an exploratory analysis, aiming at evaluating a diagnostic and/or prognostic
role of circulating miR-193a-5p in a cohort of HCC patients undergoing liver resection or LT
for early stage disease.
Materials and methods
Study design and patient characteristics
We performed this exploratory observational cohort study to evaluate a potential role of circu-
lating miR-193a-5p levels in n = 41 HCC patients undergoing surgical tumor resection
(n = 33) or liver transplantation (n = 8). HCC patients who were admitted to the Department
of Visceral and Transplantation Surgery at University Hospital RWTH Aachen for tumor
resection or LT were prospectively recruited between March 2011 and March 2017. Inclusion
criteria were: 1. Age� 18 years; 2. Histologically confirmed HCC; 3. Available blood sample
prior to surgery. Exclusion criteria were: 1. Death during or shortly after surgery (<72h) due
to surgical complications; 2. Concomitant secondary malignancy. Demographic characteristics
of the study population are shown in Table 1. Given the exploratory character of this study, we
refrained from sample size and power calculations. The individual decision for or against
tumor resection/LT was made in an interdisciplinary tumor board according to internationally
recognized standards (e.g. Milan criteria for LT). We collected blood samples prior to surgery,
centrifuged them for 10 min at 2000 g, and stored serum samples at −80˚C until use. As a con-
trol population we included a total of n = 20 healthy, cancer-free blood donors with normal
values for blood counts, C-reactive protein, kidney and liver function who are medically exam-
ined on a regular basis. The study protocol was approved by the ethics committee of the
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University Hospital RWTH Aachen, Germany (EK 206/09) and conducted in accordance with
the ethical standards laid down in the Declaration of Helsinki. Written informed consent was
obtained from the patients.
miRNA isolation from serum
300 μl serum was spiked with miScript miRNA mimic SV40 (Qiagen, Germany) for sample
normalization. 600 μl peqGOLD TriFast™ (VWR) and 150 μl chloroform were added to the
sample and mixed vigorously for 15 sec followed by an incubation at room temperature for 10





Age [years, median and range] 66 [42–82]




























Deceased during follow-up [%]:
Yes—No 68.3–31.7
HCC: hepatocellular carcinoma, BMI: body mass index, NASH: non-alcoholic steatohepatitis, ECOG PS: “Eastern
Cooperative Oncology Group” performance status.
https://doi.org/10.1371/journal.pone.0239386.t001
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min. Samples were centrifuged for 15 min at 12,000 g until complete phase separation. The
aqueous phase, containing total RNA, was precipitated with 375 μl 100% isopropanol and
1.5 μl glycogen (Fermentas, St. Leonroth, Germany) overnight at -20˚C. After centrifugation at
4˚C for 30 min (12,000 g) the pellets were washed once with 70% ethanol and centrifugation at
12000 g, 5 min and 4˚C. Precipitated RNA was resuspended in 30 μl RNase free water.
Semi-quantitative reverse transcriptase PCR (qPCR)
Total RNA was used to synthesize cDNA utilizing miScript Reverse Transcriptase Kit (Qiagen)
according to the manufacturer’s protocol, and was resuspended in suitable amounts of H2O.
cDNA samples (2 μl) were used for semi-quantitative PCR in a total volume of 25 μl using the
miScript SYBR Green PCR Kit (Qiagen) and miRNA specific primers (Qiagen) on a PCR
machine (Applied Biosystems 7300 Sequence Detection System, Applied Biosystems, Foster
City, CA). Data using the 2-ΔΔCT method were presented as relative gene expression. Data were
generated and analyzed using the SDS 2.3 and RQ manager 1.2 software packages (Applied
Biosystems). For analysis of miR-193a-5 we used the commercially available (Qiagen) primer
with the sequence UGGGUCUUUGCGGGCGAGAUGA.
Statistical analysis
Statistical analyses were performed as recently described [12]. qPCR data is displayed as rela-
tive serum levels. Shapiro-Wilk-Test was used to test for normal distribution. Non-parametric
data were compared using the Mann-Whitney-U-Test or the Kruskal-Wallis-Test for multiple
group comparisons. Correlation analyses were performed using the Spearman’s correlation
coefficient. ROC curves were generated by plotting the sensitivity against 1-specificity. Opti-
mal cut-off values for ROC curves were calculated with the Youden-Index method
(YI = sensitivity + specificity—1). Kaplan-Meier curves display the impact of realtive miR-
193a-5p levels on overall survival (OS). The Log-rank test was used to test for statistical differ-
ences between subgroups. The ideal cut-off value for the identification of patients with an
impaired OS was calculated using a univariate binary cox proportional hazard model and test-
ing for the minimum p-value in RStudio. The prognostic value of variables was further tested
by uni- and multivariate Cox regression analyses. Parameters with a p-value of< 0.250 in uni-
variate testing were included into multivariate testing. All statistical analyses were performed
with SPSS 23 (SPSS, Chicago, IL, USA) and RStudio (v1.2.5033, RStudio, Inc., Boston, MA,




A total of n = 41 early stage HCC patients either receiving tumor resection (n = 33) or liver
transplantation (LT, n = 8) were included into this exploratory analysis. The median age of the
study population was 66 years (range: 42–82 years). 70.7% of patients were male and 29.3%
female. The underlying disease etiology was distributed as follows: 7.3% hepatitis B, 24.4% hep-
atitis C, 12.2% NASH, 12.2% alcoholic liver disease and 43.9% others. The median HCC tumor
size was 4.65 cm. Table 1 provides a detailed characterization of the study population.
Circulating levels of miR-193a-5p are upregulated in HCC patients
Based on the compelling evidence on a functional of miR-193a-5p in HCC [9], we first ana-
lyzed levels of miR-193a-5p in serum samples of HCC patients. Interestingly, this analysis
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revealed significantly elevated relative miR-193a-5p levels in HCC patients compared to
healthy control samples (Fig 1A). We observed a 7.3-fold induction of rel. serum levels of miR-
193a-5p in HCC patients with a median level of 0.494 compared to 3.570 in the healthy control
samples. In ROC curve analysis, relative miR-193a-5p serum levels showed an AUC value of
0.790 for the discrimination between HCC patients and healthy controls (Fig 1B). At the opti-
mal diagnostic cut-off value of 1.533, relative miR-193a-5p levels had a sensitivity and specific-
ity of 0.732 and 0.9 regarding the diagnosis of HCC.
Serum miR-193a-5p levels and patients’ characteristics
We next aimed at identifying potential regulatory mechanisms that drive the upregulation of
circulating miR-193a-5p in HCC patients and compared relative circulating levels between
several subgroups of patients. Surprisingly, we did not observe significantly altered relative
miR-193a-5p levels in patients with different underlying liver disease etiology (Fig 2A), tumor
stage (Fig 2B), tumor grading (Fig 2C), resection status (resected patients only, Fig 2D), male
and female patients (Fig 2E) or patients with different ECOG performance status (Fig 2F).
Moreover, relative miR-193a-5p levels did not correlate with HCC tumor size (Fig 2G).
In a next step, we performed extensive correlation analysis between serum miR-193a-5p
and various standard laboratory parameters including markers of liver dysfunction (bilirubin,
AST, ALT, GGT, ALP), systemic inflammation (leucocyte count and CRP), renal dysfunction
(creatinine), established HCC tumor markers (AFP) as well as hemoglobin and the platelet
count (serum levels are displayed in S1 Table). While relative miR-193a-5p levels negatively
correlated with the platelet count (rS: -0.313, p = 0.047), we were unable to detect a correlation
between relative miR-193a-5p levels and the other laboratory parameters (S2 Table).
Fig 1. Circulating levels of miR-193a-5p are upregulated in HCC patients. (A) Relative miR-193a-5p levels are significantly upregulated
in HCC patients compared to healthy control samples. (B) Relative miR-193a-5p serum levels have an AUC value of 0.790 for the
discrimination between HCC patients and healthy controls.
https://doi.org/10.1371/journal.pone.0239386.g001
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Elevated levels of circulating miR-193a-5p predict an impaired outcome
Based on the prognostic relevance of different circulating miRNAs in the context of HCC [14],
we hypothesized that serum levels of miR-193a-5p might also be indicative for the patient’s
outcome following surgical therapy. We therefore compared the overall survival (OS) of HCC
patients with a very high relative serum levels of miR-193a-5p (above the 75th percentile) and
patients with a lower relative miR-193a-5p levels (below the 75th percentile). Here, we observed
a trend towards an impaired OS in patients with preoperative relative miR-193a-5p levels
above 5.82 (Fig 3A).
Hypothesizing that the 75th percentile might not be the optimal cut-off value, we next estab-
lished an ideal prognostic cut-off value by using a univariate binary cox proportional hazard
model and testing for the minimum p-value. Using this optimal cut-off value (3.57), we
observed a significantly reduced OS in patients with a relative miR-193a-5p serum level> 3.57
compared to patients with a relative serum level< 3.57. The median OS was only 451 days for
the subgroup of patients showing high relative miR-193a-5p levels compared to 1158 days in
those patients with a relative miR-193a-5p level below the ideal cut-off value (Fig 3B). The
Fig 2. Serum miR-193a-5p levels and patients’ characteristics. Relative miR-193a-5p levels are unaltered between patients with different underlying
liver disease etiology (A), tumor stage (B), tumor grading (C), resection status (D), male and female patients (E) or patients with different ECOG
performance status (F). Relative miR-193a-5p levels did not correlate with HCC tumor size (G).
https://doi.org/10.1371/journal.pone.0239386.g002
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prognostic relevance of a miR-193a-5p levels above our cut-off value was further confirmed by
univariate Cox-regression analysis (HR: 2.936 [1.273–6.776], p = 0.012). To exclude potential
confounders with an impact on the OS following tumor resection or LT, we subsequently per-
formed uni- and multivariate Cox-regression analyses including several clinical factors (age,
sex, ECOG PS, BMI), pathological parameters (tumor size and tumor grading) as well as sev-
eral laboratory markers including parameters of systemic inflammation (leucocyte count and
CRP), liver (bilirubin and AST) and renal (creatinine) dysfunction, established HCC tumor
markers (AFP) and others (Table 2). Importantly, relative circulating miR-193a-5p levels
turned out as an independent prognostic marker for OS (HR: 3.708 [1.354–10.159], p = 0.011,
Table 2). Together, these data argue for a previously unrecognized prognostic role of circulat-
ing miR-193a-5p in HCC patients undergoing surgical tumor resection or LT.
Discussion
Hepatocellular carcinoma (HCC) represents the fifth most common cancer worldwide and is
associated with a continuously increasing incidence in Europe or North America [15, 16]. In
the majority of cases, HCC arises in cirrhotic livers. Despite the recommendation of regular
ultrasound surveillance, potentially allowing early diagnosis, only about 30% of all patients
present with early disease stage at time of diagnosis [17]. According to Barcelona Clinic of
Liver Cancer (BCLC), patients with early disease stages (BCLC 0 or A) are candidates for com-
plete tumor removal e.g. by liver surgery of liver transplantation (LT). However, with the
introduction of novel loco-ablative and systemic treatment options it became more obvious
that beside these surgical approaches, various other therapeutic options can be offered to
patients with early disease stages, especially to those with individual factors arguing against a
surgical approach. With all these options available, the individual decision in the interdisci-
plinary tumour board whether an HCC patient with early disease stage should receive surgical
Fig 3. Elevated levels of circulating miR-193a-5p predict an impaired outcome. (A) There is a trend towards an impaired overall survival (OS) in
patients with preoperative relative miR-193a-5p levels above the 75th percentile 5.82. (B) HCC patient with a relative miR-193a-5p serum level above the
ideal prognostic cut-off value (3.57) have a significantly reduced OS compared to patients with a relative serum level< 3.57. The median OS is 451 days
for patients high relative miR-193a-5p levels compared to 1158 days for patients with a relative miR-193a-5p level below the ideal cut-off value.
https://doi.org/10.1371/journal.pone.0239386.g003
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resection / LT or rather be enrolled in a more conservative therapeutic approach is often chal-
lenging. At present, the decision for or against surgical treatment is often based on the patient’s
liver function, performance status and the technical resectability (including imaging tech-
niques and the assessment of liver function), whereas e.g. aspects of tumour biology are less
frequently considered [5]. Therefore, preoperatively available biomarkers could help to better
characterize which patients would actually benefit from surgical resection / LT in terms of a
personalized therapeutic approach.
Here, we show for the first time that circulating levels of mi-193a-5p are significantly upre-
gulated in patients with early stage HCC. The upregulation was consistent between patient
with different underlying disease conditions. Moreover, we could prove that high relative lev-
els of miR-193a-5p are associated with a significantly reduced overall survival (OS) following
tumor resection or LT. As such, the median OS was only 451 days for the subgroup of patients
showing relative miR-193a-5p levels above the ideal prognostic cut-off value of 3.57 compared
to 1158 days in those patients with a relative miR-193a-5p level below the ideal cut-off value.
Importantly, multivariate Cox-regression analysis including several clinicopathological param-
eters as well as markers of organ dysfunction and systemic inflammation revealed circulating
miR-193a-5p levels as an independent prognostic factor.
MiRNAs regulate gene expression at post-transcriptional level through a complementary
base pairing with the target mRNA, leading to mRNA degradation (in case of perfect comple-
mentation) or translation inhibition (in case of imperfect complementation). Based on their
tissue-specific expression, their rapid release into the circulation and a remarkable stability in
plasma, circulating miRNA are presently scrutinized for their capability as biomarkers for
HCC both in a diagnostic and prognostic setting [18, 19]. Measurements of circulating miR-
NAs might serve as a potential new approach for prompt and non-invasive diagnostic /
Table 2. Uni- and multivariate Cox-regression analysis for the prediction of overall survival.
univariate Cox-regression multivariate Cox-regression
Parameter p-value Hazard-Ratio (95% CI) p-value Hazard-Ratio (95% CI)
rel. miR-193a-5p levels >3.57 (dichotomized) 0.012 2.936 (1.273–6.776) 0.011 3.708 (1.354–10.159)
Age 0.464 1.015 (0.975–1.057)
Female sex (dichotomized) 0.504 0.745 (0.315–1.766)
ECOG PS (0 to 3) 0.331 1.397 (0.713–2.737)
BMI 0.712 0.986 (0.915–1.062)
HCC tumor size 0.164 1.071 (0.972–1.180) 0.307 1.061 (0.947–1.190)
Tumor grading (G1 to G3) 0.407 1.518 (0.566–4.067)
Leukocyte count 0.201 1.110 (0.946–1.304) 0.659 1.044 (0.862–1.265)
Hemoglobin 0.347 0.996 (0.988–1.004)
Platelets 0.511 1.001 (0.998–1.003)
Sodium 0.306 1.057 (0.951–1.175)
Potassium 0.374 1.431 (0.649–3.159)
AST 0.707 1.002 (0.991–1.013)
Bilirubin 0.399 0.753 (0.389–1.457)
AFP 0.589 1.000 (1.000–1.000)
Creatinine 0.358 1.708 (0.510–5.724)
CRP <0.001 1.099 (1.045–1.157) 0.002 1.085 (1.030–1.143)
miR: microRNA, HCC: hepatocellular carcinoma, ECOG PS: “Eastern Cooperative Oncology Group” performance status, BMI: Body-Mass-Index, AST: aspartate
transaminase, AFP: alpha-fetoprotein, CRP: C-reactive protein; dichotomized variables are indicated, other variables were continuous.
https://doi.org/10.1371/journal.pone.0239386.t002
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prognostic screening using real-time PCR. Hence, circulating miR-193a-5p levels were
recently discovered as biomarkers in infectious diseases as well as in bladder cancer [20, 21].
We provide evidence that, along with its function as a tumor suppressor in HCC, miR-193a-
5p represents a previously unrecognized biomarker in the context of HCC. It should be noted
that elevated serum levels of miR-193a-5p in the context of low tissue levels represent only a
contradiction of the first view, since similar regulation was described for many miRNAs [22–
24] and the specific process interconnecting intra- and extracellular miRNA levels are pres-
ently unknown. Recent studies provide evidence that miRNAs are packed into exosomes,
arguing for a directed and regulated exchange between the extra- and intracellular miRNA
pool [25]. On the other hand, miRNAs might also be passively released during cell death [26].
Thus, the miR-193a-5p represents a biologically plausible biomarker in the context of cancer
and in particular HCC. Recently, miR-193a-5p was identified as part of a cell-cycle-targeting
network of miRNAs [27]. Administration of nanoparticle-formulated miR-193a-5p inhibited
tumor progression in different mouse xenograft models, including three treatment-refractory
patient-derived tumors [27]. We and others found a significant down-regulation of miR-193a-
5p in tissue samples of different murine mouse models as well as in patients with HCC. Nota-
bly, relative serum levels of miR-193a-5p directly correlated with the patients’ survival and
indicated an unfavorable tumor biology since patients with high AFP, larger tumor diameter
and undifferentiated tumors displayed a further down-regulation of miR-193a-5p compared
to others. In vitro analysis of our and other groups demonstrated that miR-193a-5p inhibits
cell growth, cell migration and formation metastases highlighting the deep integration of miR-
193a-5p in the pathophysiology of hepatocarcinogenesis [9, 28]. Despite the currently
unknown mechanism of miRNA regulation in the serum, the striking regulation of miR-193a-
5p in the serum of HCC patients might have implications for clinical aspects of liver cancer.
Therefore, larger patient cohorts with distinct causes of underlying hepatic diseases and differ-
ential HCC stages will have to be analyzed to further test the potential of miR-193a-5p levels in
the serum as biomarkers for detection and monitoring of HCC.
The present analysis is limited by some aspects. First of all, the exploratory character of our
study (n = 41) limits its transferability to the large number of HCC patients treated in clinical
routine. Moreover, our analysis only included patients in early disease stages and therefore we
can only speculate on whether a similar regulation of miR-193a-5p is also present in patients
with more advanced disease stages, receiving e.g. systemic treatments. Moreover, our study
did not include alternative treatment approaches such as loco-regional therapies, but only ana-
lyzed patients treated with resection / LT for HCC. Thus, we cannot answer the important
question whether an HCC patient with an initial serum level above our ideal prognostic cut-
off value might have had a similar or even better outcome if treated differently. Given the
ongoing studies on adjuvant immunotherapies after resection of HCC [29], a biomarker iden-
tifying patients that should receive additional therapy after surgery could be of valuable clinical
relevance. Finally, we concentrated on the patients’ OS as a primary endpoint only. Other clin-
ical endpoints such as disease-free survival (DFS) or surgical complications should be included
in future confirmatory analyses to fully understand the prognostic relevance of circulating
miR-193a-5p in the context of HCC.
In summary, to the best of our knowledge, we show for the first time that circulating miR-
193a-5p levels might represent a valuable tool for estimating outcome in patients receiving
liver transplantation or tumor resection for early stage HCC. Our data should encourage fur-
ther multi-center clinical trials including larger patient numbers in different disease stages to
provide clearer answers regarding a potential use of miR-193a-5p as a clinical marker in the
context of HCC.
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